Teladoc Health (NYSE:TDOC) Price Target Increased to $95.00 by Analysts at Barclays

Teladoc Health (NYSE:TDOC) had its price target lifted by equities research analysts at Barclays from $80.00 to $95.00 in a note issued to investors on Tuesday, The Fly reports. The firm currently has an “equal weight” rating on the health services provider’s stock. Barclays‘s price target would suggest a potential upside of 1.06% from the company’s current price. The analysts noted that the move was a valuation call.

Several other equities research analysts have also recently issued reports on the company. JPMorgan Chase & Co. boosted their price target on Teladoc Health from $82.00 to $83.00 and gave the company an “overweight” rating in a research note on Thursday, September 19th. Royal Bank of Canada assumed coverage on Teladoc Health in a research note on Wednesday, November 27th. They issued an “outperform” rating and a $100.00 price target for the company. Cowen boosted their price target on Teladoc Health from $86.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday. UBS Group assumed coverage on Teladoc Health in a research note on Friday, January 10th. They issued a “neutral” rating and a $90.00 price target for the company. Finally, Bank of America cut Teladoc Health from a “buy” rating to a “neutral” rating and boosted their price target for the company from $82.00 to $90.00 in a research note on Thursday, January 9th. Nine analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $87.71.

Teladoc Health stock opened at $94.00 on Tuesday. Teladoc Health has a 12 month low of $48.57 and a 12 month high of $98.97. The stock’s 50 day moving average is $82.71 and its 200-day moving average is $72.24. The company has a current ratio of 6.55, a quick ratio of 6.55 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $6.80 billion, a price-to-earnings ratio of -65.28 and a beta of 1.38.

Teladoc Health (NYSE:TDOC) last posted its earnings results on Wednesday, October 30th. The health services provider reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.12. Teladoc Health had a negative return on equity of 11.23% and a negative net margin of 20.15%. The company had revenue of $137.96 million for the quarter, compared to the consensus estimate of $136.46 million. During the same quarter in the prior year, the business earned ($0.34) earnings per share. The firm’s revenue for the quarter was up 24.3% on a year-over-year basis. As a group, equities research analysts predict that Teladoc Health will post -1.55 earnings per share for the current fiscal year.

In other Teladoc Health news, insider Lewis Levy sold 2,025 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $84.00, for a total transaction of $170,100.00. Following the completion of the sale, the insider now directly owns 5,655 shares in the company, valued at $475,020. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Gabriel R. Cappucci sold 9,569 shares of the company’s stock in a transaction on Thursday, October 31st. The stock was sold at an average price of $75.00, for a total value of $717,675.00. Following the sale, the chief accounting officer now owns 10,798 shares of the company’s stock, valued at $809,850. The disclosure for this sale can be found here. Insiders have sold 68,099 shares of company stock valued at $5,151,311 over the last 90 days. Corporate insiders own 3.14% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in Teladoc Health by 2.3% during the second quarter. Vanguard Group Inc. now owns 6,285,848 shares of the health services provider’s stock worth $417,444,000 after purchasing an additional 138,464 shares during the last quarter. Waddell & Reed Financial Inc. lifted its stake in Teladoc Health by 32.5% during the second quarter. Waddell & Reed Financial Inc. now owns 2,335,837 shares of the health services provider’s stock worth $155,123,000 after purchasing an additional 572,388 shares during the last quarter. Macquarie Group Ltd. lifted its stake in Teladoc Health by 59.9% during the second quarter. Macquarie Group Ltd. now owns 1,490,807 shares of the health services provider’s stock worth $99,005,000 after purchasing an additional 558,650 shares during the last quarter. Nikko Asset Management Americas Inc. lifted its stake in Teladoc Health by 44.3% during the third quarter. Nikko Asset Management Americas Inc. now owns 1,041,327 shares of the health services provider’s stock worth $70,519,000 after purchasing an additional 319,556 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its stake in Teladoc Health by 114.7% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,041,327 shares of the health services provider’s stock worth $70,519,000 after purchasing an additional 556,269 shares during the last quarter.

About Teladoc Health

Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Recommended Story: What is the Coverage Ratio?

The Fly

Analyst Recommendations for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.